Dr. Michael J. Eblan joined Radiation Oncology Associates in 2016. Prior to joining ROA, he completed his internal medicine internship and radiation oncology residency at the University of North Carolina at Chapel Hill. He served as Chief Resident, led quality and safety initiatives to improve patient care, and designed prospective clinical investigations of circulating tumor cells as a novel biomarker for radiation treatment response. During his residency, Dr. Eblan also completed additional training in CyberKnife Robotic Radiosurgery and earned Lean Six-Sigma Yellow Belt Certification. Much of his research focused on the effects of radiation on normal tissues and the development of nanotherapeutics to improve the efficacy of chemoradiotherapy and immunotherapy at the Carolina Center of Cancer Nanotechnology Excellence (CCNE).

Dr. Eblan is trained in all aspects of radiation oncology, and has particular clinical interests in thoracic, gastrointestinal, breast, prostate, brain, head and neck, hematologic and pediatric malignancies. He is experienced with multiple radiotherapy techniques, including proton beam therapy, volumetric modulated arc therapies (VMAT), intensity modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT), CyberKnife radiosurgery, intraoperative radiotherapy (IORT), and prostate and gynecologic brachytherapy, including High Dose Rate (HDR) brachytherapy. His work has been recognized by the American Society for Radiation Oncology (ASTRO), American Association for Cancer Research (AACR), Conquer Cancer Foundation, and American Society of Clinical Oncology (ASCO).

Dr. Eblan grew up in Fairfax County and graduated with distinction as an Echols Scholar from the University of Virginia, receiving dual degrees in Biology and Economics. He then trained at the National Institutes of Health (NIH) in Bethesda, Maryland, through a postbaccalaureate Intramural Research Training Award (IRTA), and published numerous research articles on genetic alterations contributing to human disease, including in the New England Journal of Medicine. He received his medical degree from the University of Pennsylvania School of Medicine, where he was awarded the Ruth L. Kirschstein National Research Service Award (NRSA) to study cancer biology and proton radiotherapy.